Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06929143

A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema

This is an observational study in which data already collected from participants with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) is studied. In observational studies, only observations are made without participants receiving any advice or any changes to healthcare.

The eye disorders, nAMD and DME, affect the macula, the central part of the retina at the back of the eye. This leads to blurry vision or blind spots, making everyday activities like reading or sewing difficult. While nAMD is linked to aging, DME is related to diabetes. Both conditions require similar treatment to help improve vision.

Aflibercept 8 milligrams (mg) is already approved in Japan for doctors to prescribe to people with nAMD or DME. It is a drug injected into the eye. It works by blocking a protein called vascular endothelial growth factor (VEGF), which causes abnormal growth and leakage of blood vessels at the back of the eye.

The participants in this study are already receiving treatment with aflibercept 8 mg as part of their regular care from their doctors.

There is limited data available on the use of aflibercept 8 mg in Japan. Data from routine medical practice will inform treatment in Japanese and other Asian populations.

The main purpose of this study is to learn more about the disease and patient characteristics of Japanese participants with nAMD and/or DME who receive aflibercept 8 mg during their routine healthcare, and how they use it.

To learn this, the study will use 2 methods:

Method 1: Researchers will study the health details of participants when they first started aflibercept 8 mg.

Method 2: Researchers will study the participants' data collected over 1 year to see how they used aflibercept 8 mg.

The data will come from a claims database called DeSC Healthcare Inc. The data will be collected from April 2023 to March 2025 for Method 1, and from April 2023 to March 2026 for Method 2.

Researchers will only look at the information from participants in Japan.

In this study, only available data from routine care are collected. No visits or tests are required as part of this study.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Neovascular Age-related Macular Degeneration (nAMD) Diabetic Macular Edema (DME)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Bayer

Osaka, 5300001, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who are prescribed aflibercept 8 mg during the observable period from the collected data.

Exclusion criteria

  • Patients in the nAMD cohort or nAMD and DME cohort who have the ICD-10 codes for nAMD who are aged <40 years old.
  • Patients in the DME cohort or others who are aged <18 years old.
  • Female patients who have any pregnancy-related records.
  • Patients who do not have at least 365 days of continuous enrollment in the database.

Treatment and study plan

Aflibercept (Eylea, BAY86-5321)

Drug

8 mg (0.07 mL) intravitreal (IVT) injection (114.3mg/mL).

Primary outcomes

  1. Description of baseline characteristics of patients with nAMD or DME who initiated aflibercept 8 mg under real-world conditions.

    Time frame: At baseline.

  2. Description of the longitudinal patterns of treatment interval of patients with nAMD or DME who initiated aflibercept 8 mg.

    Time frame: Within 12 months.

Secondary outcomes

  1. Change of treatment interval of patients with nAMD or DME who are treated with other anti-VEGF therapy.

    Time frame: Before and 12 months after initiation of aflibercept 8 mg.

  2. Number of injections of aflibercept 8 mg in patients with nAMD or DME.

    Time frame: Within 3 months, 6 months, and 12 months after the first prescription date of aflibercept 8 mg.

  3. Predicting factors of the patterns of the treatment interval of aflibercept 8 mg in patients with nAMD or DME.

    Time frame: Within 12 months.

  4. Proportion of patients who continue the aflibercept 8 mg.

    Time frame: Within 12 months.

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Real-world Utilization Patterns of Aflibercept 8 mg in Japan: a Retrospective Descriptive Study Using the Claims Database

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Apr 16, 2025
Registry last updated
May 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.